Oncology & Precision Cancer Therapeutics This slice is part of the broader Healthcare & Biotech theme.
Oncology & Precision Cancer Therapeutics names often move on drivers that differ from the rest of Healthcare & Biotech. Isolating this segment keeps earnings logic and news flow aligned with one part of the value chain.
Membership is based on Next Big Trend classification under Healthcare & Biotech → Oncology & Precision Cancer Therapeutics. Save the list as a watchlist to track updates without rebuilding Screener filters.
| Company | |||||||
|---|---|---|---|---|---|---|---|
| CGON | CG Oncology, Inc. | $6.0B | -5.28% | -11.36% | +53.71% | +56.77% | 40 |
| AKTS | Aktis Oncology, Inc. | $1.1B | -2.00% | -24.19% | -18.97% | — | 18 |
| KURA | Kura Oncology, Inc. | $947M | -0.47% | -8.38% | +2.02% | +5.16% | 47 |
| STLN | Starling Oncology, Inc. | $655M | +4.41% | +6.94% | +86.24% | +67.00% | 83 |
| BBOT | BridgeBio Oncology Therapeutics, Inc. | $320M | -14.91% | -40.04% | -73.56% | -72.47% | 6 |
| PYXS | Pyxis Oncology, Inc. | $241M | -5.14% | -37.92% | +76.52% | +35.89% | 7 |
| ALXO | ALX Oncology Holdings Inc. | $203M | +2.46% | -34.21% | +10.62% | -31.69% | 9 |
| CHRS | Coherus Oncology, Inc. | $175M | -7.76% | -20.15% | -24.65% | -37.43% | 25 |
| CTOR | Citius Oncology, Inc. | $111M | -11.60% | -7.71% | -16.02% | -54.36% | 48 |
| CRDF | Cardiff Oncology, Inc. | $96M | -3.57% | -10.74% | -61.57% | -54.62% | 41 |
| CSBR | Champions Oncology, Inc. | $68M | -2.02% | -5.01% | -29.96% | -25.99% | 55 |
Companies classified under the Healthcare & Biotech theme and the Oncology & Precision Cancer Therapeutics sub-theme within Next Big Trend's catalog.
Yes. Signed-in users can save the current constituents from this page as a named watchlist.
No. It is a research universe for screening, not a recommendation.